ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ultragenyx Pharmaceutical, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -20.90% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.45 times
2
Flat results in Mar 26
- NET SALES(Q) Lowest at USD 136 MM
- INTEREST(Q) Highest at USD 21 MM
- OPERATING PROFIT MARGIN(Q) Lowest at -118.38 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -26.53%, its profits have fallen by -1.4%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -26.53% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ultragenyx Pharmaceutical, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ultragenyx Pharmaceutical, Inc.
-26.53%
-0.47
73.58%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.94%
EBIT Growth (5y)
-20.90%
EBIT to Interest (avg)
-10.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.49
Sales to Capital Employed (avg)
0.50
Tax Ratio
0.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-23.41
EV to EBIT
-4.49
EV to EBITDA
-4.81
EV to Capital Employed
5.29
EV to Sales
3.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-117.74%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at USD -314 MM
ROCE(HY)
Highest at 0%
RAW MATERIAL COST(Y)
Fallen by 1.26% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -330.08 %
DEBTORS TURNOVER RATIO(HY)
Highest at 6.02 times
-13What is not working for the Company
NET SALES(Q)
Lowest at USD 136 MM
INTEREST(Q)
Highest at USD 21 MM
OPERATING PROFIT MARGIN(Q)
Lowest at -118.38 %
PRE-TAX PROFIT(Q)
Lowest at USD -184 MM
NET PROFIT(Q)
Lowest at USD -185 MM
EPS(Q)
Lowest at USD -1.84
Here's what is working for Ultragenyx Pharmaceutical, Inc.
Debt-Equity Ratio
Lowest at -330.08 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 6.02 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 1.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ultragenyx Pharmaceutical, Inc.
Net Sales
At USD 136 MM has Fallen at -19.13%
over average net sales of the previous four periods of USD 168.18 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Net Sales
Lowest at USD 136 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Interest
Highest at USD 21 MM
in the last five periods and Increased by 10.53% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Profit Margin
Lowest at -118.38 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at USD -184 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -184 MM has Fallen at -28.71%
over average net sales of the previous four periods of USD -142.96 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -185 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Net Profit
At USD -185 MM has Fallen at -28.48%
over average net sales of the previous four periods of USD -143.99 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD -1.84
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
